(ACHV) Achieve Life Sciences - NASDAQ
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 527m USD | Total Return: 54.6% in 12m
Avg Turnover: 6.38M
Qual. Beats: 1
Qual. Beats: 0
Warnings
Share dilution 53.9% YoY
Interest Coverage Ratio -56.9 is critical
Altman Z'' -15.00 < 1.0 - financial distress zone
Fakeout Choppy
Tailwinds
Confidence
Achieve Life Sciences (ACHV) is a late-stage pharmaceutical company focused on the development and commercialization of cytisinicline, a plant-based alkaloid designed to aid nicotine cessation. The company operates primarily in the United States, Canada, and the United Kingdom, utilizing a business model centered on licensing and supply partnerships with entities such as Sopharma AD and the University of Bristol.
The biotechnology sector often faces high capital requirements and lengthy regulatory pathways, particularly for companies transitioning from clinical trials to commercialization. As a nicotine-dependence specialist, Achieve Life Sciences targets a specific therapeutic niche by developing treatments that interact with brain receptors to mitigate withdrawal symptoms. For a deeper look into the companys financial health and valuation metrics, ValueRay provides comprehensive analytical tools. Achieving FDA approval remains the critical milestone for late-stage biotech firms seeking to enter the competitive smoking cessation market.
- FDA New Drug Application filing for cytisinicline triggers major valuation re-rating
- Phase 3 ORCA-OL trial data determines long-term safety profile and approval
- Strategic partnership or buyout potential hinges on smoking cessation market entry
- Ongoing capital requirements for commercialization infrastructure increase dilution risk for shareholders
- Sopharma supply chain stability impacts global manufacturing and distribution capacity
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -1.37 > 0.02 and ΔFCF/TA -6.86 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -1.37 > 3% & CFO -45.3m > Net Income -52.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.62 > 1.5 & < 3 |
| Outstanding Shares: last quarter (53.4m) vs 12m ago 53.90% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.83%; Δ -0.83% > 0%) |
| Interest Coverage Ratio: -56.88 > 6 (EBIT TTM -51.6m / Interest Expense TTM 908k) |
| A: 0.58 (Total Current Assets 31.1m - Total Current Liabilities 11.8m) / Total Assets 33.1m |
| B: -8.17 (Retained Earnings -270.4m / Total Assets 33.1m) |
| C: -1.71 (EBIT TTM -51.6m / Avg Total Assets 30.2m) |
| D: 0.48 (Book Value of Equity 10.7m / Total Liabilities 22.4m) |
| Altman-Z'' = -33.80 = D |
As of June 12, 2026, the stock is trading at USD 5.52 with a total of 2,768,869 shares traded.
Over the past week, the price has changed by +4.35%,
over one month by -1.25%,
over three months by +26.03% and
over the past year by +54.62%.
Achieve Life Sciences has received a consensus analysts rating of 4.88. Therefore, it is recommended to buy ACHV.
- StrongBuy: 7
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 13.1 | 137.5% |
P/E Forward = 35.3357
P/S = 5.087
P/B = 49.224
P/EG = 17.6808
Revenue TTM = 0.0 USD
EBIT TTM = -51.6m USD
EBITDA TTM = -51.4m USD
Long Term Debt = 9.32m USD (from longTermDebt, last quarter)
Short Term Debt = 5.63m USD (from shortTermDebt, last quarter)
Debt = 15.0m USD (from shortLongTermDebtTotal, last quarter) + Leases 51.0k
Net Debt = -14.3m USD (calculated: Debt 15.0m - CCE 29.3m)
Enterprise Value = 512.4m USD (526.6m + Debt 15.0m - CCE 29.3m)
Interest Coverage Ratio = -56.88 (Ebit TTM -51.6m / Interest Expense TTM 908k)
EV/FCF = -11.31x (Enterprise Value 512.4m / FCF TTM -45.3m)
FCF Yield = -8.84% (FCF TTM -45.3m / Enterprise Value 512.4m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 223k) / Revenue TTM)
Tobins Q-Ratio = 15.48 (Enterprise Value 512.4m / Total Assets 33.1m)
Interest Expense / Debt = 6.05% (Interest Expense 908k / Debt 15.0m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -40.8m (EBIT -51.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.62 (Total Current Assets 31.1m / Total Current Liabilities 11.8m)
Debt / Equity = 1.41 (Debt 15.0m / totalStockholderEquity, last quarter 10.7m)
Debt / EBITDA = 0.28 (negative EBITDA) (Net Debt -14.3m / EBITDA -51.4m)
Debt / FCF = 0.31 (negative FCF - burning cash) (Net Debt -14.3m / FCF TTM -45.3m)
Total Stockholder Equity = 26.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -172.0% (out of range, set to none)
RoE = -193.5% (Net Income TTM -52.0m / Total Stockholder Equity 26.9m)
RoCE = -142.7% (out of range, set to none) (EBIT -51.6m / Capital Employed (Equity 26.9m + L.T.Debt 9.32m))
RoIC = -151.7% (out of range, set to none) (NOPAT -40.8m / Invested Capital 26.9m)
WACC = 10.32% (E(526.6m)/V(541.6m) * Re(10.48%) + D(15.0m)/V(541.6m) * Rd(6.05%) * (1-Tc(0.21)))
Discount Rate = 10.48% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 98.88 | Cagr: 50.86%
[DCF] Fair Price = unknown (Cash Flow -45.3m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 3.20 | # QB: 1
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.15 | Chg30d=+54.55% | Revisions=+60% | Analysts=8
EPS next Quarter (2026-09-30): EPS=-0.16 | Chg30d=+51.25% | Revisions=+60% | Analysts=8
EPS current Year (2026-12-31): EPS=-0.69 | Chg30d=+47.54% | Revisions=+64% | GrowthEPS=+44.6% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-0.46 | Chg30d=+55.33% | Revisions=+60% | GrowthEPS=+33.0% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +64%